New research from The University of Queensland shows that seven compounds of the countless found in spider venom block a key step in the body’s ability to pass pain signals to the brain. The hunt for a medicine based on just one of these compounds, which would open up a new class of potent painkillers, is now a step closer according to new research published in the British Journal of Pharmacology.
Pain that cannot be controlled can ruin people’s lives. One in five people worldwide currently suffer from chronic pain, and existing pain treatments often fail to provide relief. The economic burden is huge, with chronic pain in the USA alone estimated to cost around $600 billion a year, greater than the combined economic cost of cancer, diabetes and stroke.
The team explain that people sense that part of their body is hurting when nerves from the affected area send signals to the brain through what is called the pain pathway adding that a compound that blocks Nav1.7 channels is of particular interest. Previous research shows indifference to pain among people who lack Nav1.7 channels due to a naturally-occurring genetic mutation, so blocking these channels has the potential of turning off pain in people with normal pain pathways.
Part of the search for new medicines has focused on the world’s 45,000 species of spiders, many of which kill their prey with venoms that contain hundreds, or even thousands, of protein molecules. Some of these molecules are shown to block nerve activity.
The team state that a conservative estimate indicates that there are nine million spider-venom peptides, and only 0.01% of this vast pharmacological landscape has been explored so far. The challenge was to build a research method that could search through this huge number of peptides, looking for the ones that could be useful.
Taking up this challenge, the researchers built a system that could rapidly analyse the compounds in spider venoms. Using their novel approach, venoms from 206 species of spider were screened, revealing that 40% of the venoms contained at least one compound that blocked human Nav1.7 channels.
Of the seven promising compounds identified, they discovered one that was particularly potent, and also had a chemical structure that suggested it would have high levels of chemical, thermal, and biological stability, which would be essential for administering a new medicine. Together these properties make it particularly exciting as a potential painkiller.
The team summise that untapping this natural source of new medicines brings a distinct hope of accelerating the development of a new class of painkillers that can help people who suffer from chronic pain that cannot be treated with current treatment options. The novel screening approach used to isolate the protein molecules from spider venoms could also be applied to other compounds, opening up hope more widely for new and better medicines.
The next step is to continue exploring the clinical potential of these peptides.
Source: University of Queensland
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.